Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.55 |
| ▸ | ABL1 | P00519 | 3/20 | 0.55 |
| ▸ | CDK2 | P24941 | 12/20 | 0.44 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.43 |
| ▸ | CDK4 | P11802 | 7/20 | 0.41 |
| ▸ | USP7 | Q93009 | 1/20 | 0.39 |
| ▸ | CDK1 | P06493 | 1/20 | 0.38 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.38 |
| ▸ | CCND1 | P24385 | 1/20 | 0.38 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24285993 | 0.87 | LRRK2 (0.42) | LRRK2ABL1CDK2TGFBR1USP7 | |
| SCHEMBL24285885 | 0.78 | LRRK2 (0.41) | LRRK2ABL1CDK2TGFBR1CDK4 | |
| SCHEMBL29537111 | 0.77 | LRRK2 (0.65) | LRRK2ABL1CDK2CDK4CDK1 | |
| SCHEMBL29538250 | 0.77 | LRRK2 (0.65) | LRRK2ABL1CDK2CDK4CDK1 | |
| SCHEMBL24286637 | 0.77 | LRRK2 (0.65) | LRRK2ABL1CDK2CDK4CDK1 | |
| SCHEMBL24285954 | 0.77 | LRRK2 (0.65) | LRRK2ABL1CDK2CDK4CDK1 | |
| SCHEMBL24285971 | 0.76 | LRRK2 (0.42) | LRRK2ABL1CDK2TGFBR1CDK4 | |
| SCHEMBL24286618 | 0.76 | LRRK2 (0.40) | LRRK2ABL1CDK2TGFBR1CDK4 | |
| SCHEMBL24286579 | 0.75 | ABL1 (0.47) | LRRK2ABL1TGFBR1USP7 | |
| SCHEMBL1322438 | 0.75 | CYP11B1 (0.50) | CDK2CDK4USP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11744824-B2 | 2-amino-3-carbonyl imidazopyridine and pyrazolopyridine compounds | 1ST Biotherapeutics, Inc. (KR) | 2023-09-05 | — | — | US | disclosed |
| US-20220087985-A1 | 2-AMINO-3-CARBONYL IMIDAZOPYRIDINE AND PYRAZOLOPYRIDINE COMPOUNDS | 1ST Biotherapeutics, Inc. (KR) | 2022-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11744824-B2 | 2-amino-3-carbonyl imidazopyridine and pyrazolopyridine compounds | NLRP3, NLRP1, KCNJ2 | LRRK2 538/4885ABL1 966/4885CDK2 952/4885 |
| US-20220087985-A1 | 2-AMINO-3-CARBONYL IMIDAZOPYRIDINE AND PYRAZOLOPYRIDINE COMPOUNDS | NLRP3, NLRP1, KCNJ2 | LRRK2 538/4885ABL1 966/4885CDK2 952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.